For years, the cornerstone of first-line treatment for advanced HER2-positive gastric cancer has predominantly been chemotherapy, supplemented with targeted therapy using trastuzumab, an anti-HER2 monoclonal antibody1. The gene discussed is ERBB2; the disease is gastric cancer.